On The Fly
| ShowHide Related Items >><< - 08/10/22
- Wallbox acquires EV charging installation services company COIL
- 08/01/22
- Wallbox, EVmatch announce partnership
- 06/22/22
- Nissan, Wallbox to offer seamless home charging solution for Nissan EV owners
- 04/11/22
- Wallbox begins Arlington manufacturing facility construction
- 09/06/22
- Veritex: StoneCastle Partners terminated pact for its StoneCastle Insured buy
- 07/18/22
- Veritex expands SBA Lending department
- 03/09/22
- Veritex director Arcilia Acosta acquires 26,316 common shares
- 03/09/22
- Veritex director Pat Bolin acquires 13,158 common shares
- 08/25/22
- Cathie Wood's ARK Investment bought 50.3K shares of Teladoc today
- 08/25/22
- Teladoc, Amwell rise after Amazon says will shut down Amazon Care
- 08/17/22
- Cathie Wood's ARK Investment bought 311K shares of Teladoc today
- 08/11/22
- Cathie Wood's ARK Investment bought 101K shares of Teladoc today
- 09/06/22
- Ryman Hospitality announces new 10c interim dividend
- 06/01/22
- Ryman Hospitality sees FY adjusted EBITDA $494M-$520M
- 06/01/22
- Ryman Hospitality closes acquisition of Block 21 from Stratus Properties
- 05/02/22
- Ryman Hospitality sees FY22 adjusted EBITDAre $476M-$502M
- 09/07/22
- Pinterest rises 6.9%
- 08/31/22
- Pinterest rises 7.2%
- 08/15/22
- Elliott buys Pinterest, exits Twitter in Q2
- 08/04/22
- Pinterest CEO buys $5M in common stock
- 09/07/22
- UiPath falls -17.0%
- 09/07/22
- UiPath falls -19.7%
- 09/07/22
- UiPath expands pact with Snowflake with bi-directional integration
- 08/10/22
- UiPath names Brigette McInnis-Day chief people officer
- 08/30/22
- Novartis presents new data in breast and prostate cancer at ESMO
- 08/25/22
- Novartis announces intention to spin-off biosimilars division Sandoz
- 08/16/22
- Novartis's treatment of ALS granted FDA orphan designation
- 08/15/22
- Novartis' treatment of Malaria granted FDA orphan designation
- 08/31/22
- NetEase acquires Quantic Dream, terms undisclosed
- 08/18/22
- NetEase raises quarterly dividend to 36c from 32.2c per ADS
- 07/25/22
- NetEase launches Diablo Immortal in Chinese market on Android, iOS
- 07/21/22
- NetEase Cloud Music granted right to distribute YG Entertainment music catalog
- 08/28/22
- Fly Intel: Top five weekend stock stories
- 08/15/22
- Pershing Square exits Netflix in Q2
- 07/19/22
- Netflix plans to spend roughly $17B on content over next few years
- 07/19/22
- Netflix plans wider rollout for paid sharing next year
- 07/18/22
- Medpace CEO buys $3.22M in common stock
- 08/16/22
- GMS Inc. names Leigh Dobbs Chief Human Resources Officer
- 07/22/22
- GMS Inc. promotes Travis Hendren as COO
- 08/09/22
- GoodRx rallies after saying grocer issue recently addressed
- 05/17/22
- GoodRx announces strategic relationship with RxVantage
- 05/09/22
- GoodRx 'unlikely' to achieve guidance provided on Q4 earnings call
- 05/09/22
- GoodRx names former Uber grocery, new verticals chief Raj Beri as COO
- 08/29/22
- Electronic Arts exec sells $903K in common stock
- 08/26/22
- Electronic Arts off highs after CNBC's Faber says Amazon not planning bid
- 08/26/22
- Electronic Arts off highs after CNBC says Amazon not expected to bid
- 08/19/22
- Warner Bros.' 'MultiVersus' best-selling U.S. game in July, says NPD
- 08/05/22
- Doximity falls -15.2%
- 06/16/22
- Doximity 'comfortable' with guidance for the year, quarter
- 05/18/22
- Doximity falls -14.7%
- 05/17/22
- Doximity falls over 17% to $27.90 after Q4 results, below-consensus Q1 guidance
- 08/31/22
- ChargePoint rises 12.6%
- 08/31/22
- ChargePoint rises 10.7%
- 08/09/22
- Starbucks, Volvo,ChargePoint team on EV charger spots on Denver to Seattle route
- 07/27/22
- ChargePoint and Charge Across Town team with CA on EV charger deployment
- 05/05/22
- Bilibili provides update on status under HFCAA
- 05/02/22
- Bilibili provides update on voluntary conversion to dual-primary listing
- 09/07/22 Jefferies
- Netflix price target lowered to $230 from $243 at Jefferies
- 09/07/22 Macquarie
- Macquarie upgrades Netflix to Neutral on longer term upside from ads
- 09/07/22 Macquarie
- Netflix upgraded to Neutral from Underperform at Macquarie
- 08/31/22 Citi
- Snap downgraded to Neutral from Buy at Citi
- 09/07/22 Wolfe Research
- Pinterest upgraded to Outperform from Peer Perform at Wolfe Research
- 08/02/22 Evercore ISI
- Pinterest price target raised to $28 from $24 at Evercore ISI
- 08/02/22 Baird
- Pinterest results for Q2 better than feared, says Baird
- 08/02/22 Citi
- Pinterest price target raised to $25 from $24 at Citi
- 09/07/22 Truist
- Ryman Hospitality upgraded to Buy at Truist on corporate group exposure
- 09/07/22 Truist
- Ryman Hospitality upgraded to Buy from Hold at Truist
- 08/03/22 Deutsche Bank
- Ryman Hospitality price target raised to $121 from $116 at Deutsche Bank
- 06/23/22 Citi
- Citi adds AutoZone, Thermo Fisher, Ionis to 'Focus List'
- 09/07/22 JPMorgan
- Bilibili assumed at Overweight from Neutral at JPMorgan
- 08/01/22 Goldman Sachs
- Bilibili received one China game approval for August, says Goldman Sachs
- 06/13/22 JPMorgan
- Bilibili price target raised to $25 from $19 at JPMorgan
- 06/10/22 Citi
- Bilibili price target lowered to $45 from $46 at Citi
- 09/07/22 Kepler Cheuvreux
- Novartis upgraded to Buy from Hold at Kepler Cheuvreux
- 08/05/22 Truist
- Global Blood could complement any oncology franchise, says Truist
- 08/04/22 Truist
- Truist sees Novartis, Vertex as logical suitors for Global Blood
- 07/20/22 JPMorgan
- Novartis price target raised to CHF 81 from CHF 80 at JPMorgan
- 09/07/22 MKM Partners
- MKM Partners cuts Electronic Arts to Neutral on further margin contraction
- 09/07/22 MKM Partners
- Electronic Arts downgraded to Neutral from Buy at MKM Partners
- 08/29/22 Citi
- Amazon deal for Electronic Arts would bring regulatory risks, says Citi
- 08/26/22 Benchmark
- EA could be valued at $188 per share in competitive process, says Benchmark
- 09/07/22 JPMorgan
- NetEase assumed with Neutral from Overweight at JPMorgan
- 08/19/22 Citi
- NetEase price target raised to $140 from $132 at Citi
- 07/05/22 Macquarie
- China online gaming re-ratings 'about to begin,' says Macquarie
- 09/07/22 Canaccord
- UiPath downgraded to Hold at Canaccord after 'largely disappointing' Q2 report
- 09/07/22 Canaccord
- UiPath downgraded to Hold from Buy at Canaccord
- 09/07/22 Truist
- UiPath price target lowered to $25 from $45 at Truist
- 09/07/22 BMO Capital
- UiPath price target lowered to $15 from $21 at BMO Capital
- 09/07/22 Truist
- Truist cuts GMS Inc. to Hold on impact from downturn in residential construction
- 09/07/22 Truist
- GMS Inc. downgraded to Hold from Buy at Truist
- 06/24/22 Truist
- GMS Inc. price target lowered to $50 from $65 at Truist
- 06/24/22 Baird
- GMS Inc. price target lowered to $55 from $68 at Baird
- 09/07/22 Stephens
- Stephens downgrades Veritex, sees bank in 'difficult position' after deal nixed
- 09/07/22 Stephens
- Veritex downgraded to Equal Weight from Overweight at Stephens
- 07/07/22 Raymond James
- Veritex downgraded to Outperform from Strong Buy at Raymond James
- 07/07/22 Raymond James
- Veritex downgraded to Outperform from Strong Buy at Raymond James
- 09/07/22 Truist
- Teladoc initiated with a Hold at Truist
- 09/02/22 Piper Sandler
- Teladoc long-term thesis remains intact, says Piper Sandler
- 08/17/22 Guggenheim
- Guggenheim cuts Teladoc to Sell with growth remaining pressured
- 08/17/22 Guggenheim
- Teladoc downgraded to Sell from Neutral at Guggenheim
- 09/07/22 Truist
- Doximity initiated with a Hold at Truist
- 08/23/22 Canaccord
- Doximity estimates updated to within guidance range at Canaccord
- 08/05/22 Canaccord
- Doximity price target lowered to $42 from $47 at Canaccord
- 08/05/22 BofA
- Doximity downgraded to Underperform on customer pullback at BofA
- 09/07/22 Credit Suisse
- ChargePoint initiated with an Outperform at Credit Suisse
- 08/31/22 Oppenheimer
- ChargePoint results strong despite supply headwinds, says Oppenheimer
- 08/31/22 JPMorgan
- ChargePoint leadership remains underappreciated, says JPMorgan
- 08/23/22 JPMorgan
- ChargePoint price target raised to $20 from $18 at JPMorgan
- 09/07/22 Credit Suisse
- Wallbox initiated with an Outperform at Credit Suisse
- 08/11/22 Stifel
- Wallbox price target lowered to $20 from $24 at Stifel
- 08/04/22 Barclays
- Wallbox initiated with an Overweight at Barclays
- 07/13/22 Canaccord
- Wallbox initiated with a Buy at Canaccord
- 09/07/22 UBS
- Medpace initiated with a Sell at UBS
- 05/23/22 Guggenheim
- Medpace initiated with Neutral on pre-revenue focus at Guggenheim
- 05/23/22 Guggenheim
- Medpace initiated with a Neutral at Guggenheim
- 03/17/22 Baird
- Medpace price target raised to $175 from $160 at Baird
- 09/07/22 UBS
- Icon initiated with a Buy at UBS
- 08/24/22 Credit Suisse
- Icon initiated with a Neutral at Credit Suisse
- 07/29/22 Deutsche Bank
- Icon price target raised to $295 from $285 at Deutsche Bank
- 07/14/22 Deutsche Bank
- Icon price target lowered to $285 from $310 at Deutsche Bank
- 09/07/22 Truist
- GoodRx initiated with a Hold at Truist
- 08/11/22 DA Davidson
- GoodRx initiated with a Neutral at DA Davidson
- 08/09/22 Goldman Sachs
- Goldman Sachs raises GoodRx price target to $10 amid grocer issue resolution
- 08/09/22 RBC Capital
- GoodRx price target raised to $11 from $6.50 at RBC Capital
- 07/27/22
- Veritex reports Q2 EPS 55c, consensus 69c
- 07/27/22
- Teladoc cuts FY22 EPS view to ($62.00)-($61.00) from ($43.50)-($43.00)
- 07/27/22
- Teladoc sees Q3 EPS (85c)-(60c), consensus (55c)
- 07/27/22
- Teladoc reports Q2 EPS ($19.22), consensus (64c)
- 07/27/22
- Notable companies reporting after market close
- 05/02/22
- Ryman Hospitality reports Q1 AFFO 63c, consensus 88c
- 08/01/22
- Pinterest sees Q3 revenue growth mid-single digits, consensus $713.47M
- 08/01/22
- Pinterest reports Q2 adjusted EPS 11c, consensus 18c
- 08/01/22
- Notable companies reporting after market close
- 04/27/22
- Pinterest sees Q2 revenue up 11% y/y, consensus $692.5M
- 09/06/22
- UiPath sees FY23 revenue $1.00B-$1.01B, consensus $1.09B
- 09/06/22
- UiPath sees Q3 revenue $243M-$245M, consensus $269.6M
- 09/06/22
- UiPath reports Q2 EPS (2c), consensus (11c)
- 09/06/22
- Notable companies reporting after market close
- 07/19/22
- Novartis reports Q2 core EPS $1.56 vs. $1.66 a year ago
- 04/26/22
- Novartis sees 2022 core operating income to grow mid single digit
- 04/26/22
- Novartis reports Q1 core EPS $1.46, consensus $1.46
- 08/18/22
- NetEase reports Q2 EPS $1.23 vs. $1.17 a year ago
- 07/19/22
- Netflix sees Q3 EPS $2.14, consensus $2.77
- 07/19/22
- Netflix reports Q2 EPS $3.20, consensus $2.96
- 07/19/22
- Notable companies reporting after market close
- 04/19/22
- Netflix sees Q2 EPS $3.00, consensus $3.01
- 07/25/22
- Medpace raises FY22 EPS view to $6.07-$6.36 from $5.72-$6.06
- 07/25/22
- Medpace reports Q2 EPS $1.46, consensus $1.31
- 04/25/22
- Medpace sees FY22 EPS $5.72-$6.06, consensus $5.61
- 04/25/22
- Medpace reports Q1 EPS $1.69, consensus $1.26
- 07/27/22
- Icon sees FY22 adjusted EPS $11.65-$11.85, consensus $11.58
- 07/27/22
- Icon reports Q2 adjusted EPS $2.86, consensus $2.80
- 04/27/22
- Icon affirms FY22 EPS view of $11.55-$11.95, consensus $11.73
- 04/27/22
- Icon reports Q1 EPS $2.76, consensus $2.70
- 09/01/22
- GMS Inc. reports Q1 adjusted EPS $2.43, consensus $2.25
- 06/23/22
- GMS Inc. reports Q4 adjusted EPS $2.09, consensus $1.88
- 08/08/22
- GoodRx sees Q3 revenue roughly $185M, consensus $201.4M
- 08/08/22
- GoodRx reports Q2 adjusted EPS 6c, consensus 4c
- 08/08/22
- Notable companies reporting after market close
- 05/09/22
- GoodRx sees Q2 revenue about $190M, consensus $215.62M
- 08/02/22
- Electronic Arts sees FY23 revenue $7.6B-$7.8B, consensus $7.99B
- 08/02/22
- Electronic Arts reports Q1 EPS $1.11 vs. 71c last year
- 08/02/22
- Notable companies reporting after market close
- 05/10/22
- Electronic Arts sees Q1 EPS 76c-85c, consensus 83c
- 08/04/22
- Doximity lowers FY23 revenue view to $424M-$432M from $454.0M-$458.0M
- 08/04/22
- Doximity sees Q2 revenue $99.5M-$100.5M, consensus $105.26M
- 08/04/22
- Doximity reports Q1 non-GAAP EPS 14c, consensus 10c
- 05/17/22
- Doximity raises FY23 revenue view to $454.0M-$458.0M from $450M
- 08/30/22
- ChargePoint backs FY23 revenue view $450M-$500M, consensus $476.47M
- 08/30/22
- ChargePoint sees Q3 revenue $125M-$135M, consensus $130M
- 08/30/22
- ChargePoint reports Q2 EPS (28c) vs (29c) last year
- 05/31/22
- ChargePoint sees Q2 revenue 96M-$106M, consensus $105.59M
- 06/09/22
- Bilibili sees Q2 revenue RMB4.85B-RMB4.95B from RMB5.05B in Q1
- 06/09/22
- Bilibili reports Q1 adjusted EPS (66c), consensus (62c)
- 06/08/22
- Notable companies reporting before tomorrow's open
|